[Form 4] Guardant Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Manuel Hidalgo Medina, a director of Guardant Health, Inc. (GH), reported transactions dated 09/17/2025 showing the acquisition of 232 restricted stock units (RSUs) at $0 pursuant to vesting (Transaction Code M). The Form 4 shows 1,083 shares of common stock held following a separate non-derivative entry and 7,889 shares beneficially owned following the reported derivative transactions. The filing notes the RSU award was granted on July 17, 2024 and vests over four years: 25% vested at the one-year anniversary and the remaining 75% vests monthly over the following three years. The form is signed by an attorney-in-fact on 09/18/2025.

Positive

• Transparent disclosure of RSU vesting and resulting share ownership for a company director
• Vesting-based acquisition (Code M) indicates alignment with long-term compensation rather than immediate sale

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Director received vesting RSUs consistent with standard multi-year equity compensation; no sales or external transfers reported.

The Form 4 discloses a routine vesting event for an RSU grant originally issued July 17, 2024, with 232 units recorded as acquired on September 17, 2025 under Code M, indicating vesting rather than a market transaction. The filing shows total beneficial ownership counts of 1,083 shares (non-derivative) and 7,889 shares (derivative/underlying), reflecting the director's current holdings as reported. This disclosure aligns with customary governance practices to compensate directors with equity that vests over time and provides transparency to shareholders.

Securities/Insider Trading Analyst

TL;DR: Reported activity is a vesting event converting RSUs into common shares; no cash purchase or sale occurred.

The entry uses Transaction Code M and shows a $0 price, consistent with RSU vesting and conversion into common stock rather than an open-market trade. The report updates the director's beneficial ownership totals to 1,083 shares (non-derivative) and 7,889 shares (post-derivative conversion). The signature by an attorney-in-fact on 09/18/2025 completes the timely disclosure obligation under Section 16. There are no indications of disposals, option exercises for cash, or other market-impacting transactions in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Hidalgo Medina Manuel

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2025		M		232	A	$0	1,083	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	09/17/2025		M			232	(1)	(2)	Common Stock	232	$0	7,889	D

Explanation of Responses:

1. The restricted stock unit award granted on July 17, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of July 17, 2024. The remaining 75% vests monthly during the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Manuel Hidalgo Medina	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Guardant Health director Manuel Hidalgo Medina report on Form 4?

The Form 4 reports the acquisition by vesting of 232 RSUs on 09/17/2025, with updated beneficial ownership totals of 1,083 common shares (non-derivative) and 7,889 shares following the derivative conversion.

What does Transaction Code M mean on this Form 4 for GH?

Transaction Code M is used here to indicate the settlement of a non-derivative award upon vesting (the filing shows a $0 price consistent with RSU vesting).

When was the RSU grant originally awarded to the reporting person?

The RSU award was granted on July 17, 2024 and vests over four years: 25% at the one-year anniversary and the remaining 75% monthly over the next three years.

Did the director sell any shares in this Form 4 filing for GH?

No. The filing shows acquisitions via vesting and a $0 price; there are no reported disposals or sales in this Form 4.

Who signed the Form 4 for Manuel Hidalgo Medina and when?

The Form 4 was signed by John G. Saia, as attorney-in-fact for Manuel Hidalgo Medina on 09/18/2025.